Adriamycin cardiotoxicity: report of an unusual case with features resembling endomyocardial fibrosis

W FITTER,* DJ deSA,* KRM PAI†
From the Departments of *Pathology & †Pediatrics, McMaster University Medical Centre, Hamilton, Ontario, Canada

SUMMARY We report on a case of adriamycin cardiotoxicity occurring in a five-year-old boy treated for rhabdomyosarcoma. In addition to the usual features of myofibrillar degeneration associated with adriamycin, extreme endocardial fibrosis and mural thrombosis affecting the apical segments of both ventricles but particularly the left ventricle was seen at necropsy. The changes resembled classical endomyocardial fibrosis.

Adriamycin is an antineoplastic drug and is effective against a variety of solid tumours. Several side effects including alopecia, stomatitis, and bone marrow suppression have been reported.1 However, the major side effect which has restricted its use is that of cardiotoxicity.2,3

We describe a case of adriamycin cardiotoxicity showing extremely unusual, and apparently previously unreported, gross morphological changes, characterised by extreme endocardial and myocardial fibrosis resulting in a lesion that resembled endomyocardial fibrosis.4

Case report

A five-year-old boy was admitted for investigation of abdominal pain, fever and dysuria which had been present for four weeks before admission. Physical examination showed a rounded, tender, firm mass approximately 8 cm in diameter, located in the right lower quadrant of the abdomen. No other abnormality was noted on physical examination and in particular, there were neither heart murmurs nor any evidence of heart disease. An intravenous pyelogram confirmed the presence of a mass on the pelvic brim on the right side, with associated right hydrourereter and hydronephrosis. A chest x-ray examination showed no abnormality. Laboratory investigations did not further a diagnosis. At laparotomy a firm, fleshy tumour mass adherent to the right pelvic wall and urinary bladder was identified. No metastases were seen in the field of operation, nor were any palpable elsewhere in the abdomen. A partial resection was performed, and histological examination of the tumour showed characteristic features of an embryonal rhabdomyosarcoma, with recognisable striations in the numerous strap cells of the tumour. Two weeks after surgery, combination chemotherapy was started, consisting of dactinomycin, cyclophosphamide and vincristine. In addition, the lower abdomen was irradiated for 21 days resulting in a total dosage of 5200 r. The chest and mediastinum were not irradiated.

He developed severe neuropathy, three months after starting chemotherapy and this was attributed to vincristine treatment. Vincristine was discontinued and adriamycin treatment was introduced at a dosage of 60 mg/m². At this point, electrocardiogram and haematological indices were normal. His neuropathic symptoms improved and electromyographic abnormalities returned to normal. Vincristine treatment restarted after two month delay without recurrence of neurotoxicity. Eight months after the operation he was readmitted with anorexia and abdominal pain. A moderate increase in heart size was noted in a chest x-ray film, and echocardiogram results showed slight dilatation of the left ventricle. Electrocardiographic changes included reduced voltage and non-specific T wave changes. Adriamycin cardiotoxicity was diagnosed and the drug was discontinued. At this point the total cumulative dosage of adriamycin was less than 250 mg/m².

Over the next seven months he developed congestive cardiac failure, which was associated with increasing cardiomegaly and a grade 3 or 4 apical, systolic murmur. His congestive cardiac failure proved refractory to conventional medical treatment and he continued to suffer from severe dyspnoea and generalised oedema. No evidence of tumour pro-
Adriamycin cardiotoxicity: report of an unusual case

Regression was noted. Sixteen months after the operation he suffered a cardiac arrest and died.

**Necropsy findings**

At necropsy, the original site of the tumour was replaced by scar tissue admixed with vascular granulation tissue and no residual tumour was found. No metastases were found either locally or elsewhere. The principal findings were in the heart. It weighed 200 g with moderate dilatation of both ventricles and atria. No congenital anomalies were noted and the coronary vessels were normal. There was, however, increased fibrosis of the trabeculae carnae in the apical areas of both ventricles, with extensive overlying mural thrombosis. The change was most marked in the left ventricle. Here the fibrotic changes extended from the apex, over the posterior and interior walls, and into the left ventricular outflow tract where it was demarcated by a sharp, upper margin (Fig. 1). The involvement of the chordae tendinae was associated with moderate dilatation of the mitral valve (17 cm). These features were reminiscent of endomyocardial fibrosis.

Histological examination of multiple blocks from several areas of the myocardium showed similar features. In all areas there was extensive interstitial fibrosis, with decreased numbers of muscle fibres. Many of the surviving fibres showed vacuolation, variation of nuclear size and shape and blurring of the cross striations (Fig. 2). The thickened, fibrotic areas of endocardium showed the presence of organising, lamellar, thrombus. In the deeper strata, occasional bundles of degenerated myocardial fibres were present. The fibrous tissue of the organising lamellar thrombus merged with the areas of interstitial fibrosis (Fig. 3). No inflammatory infiltrate was noted.

**Ultrastructural findings**

At the time of necropsy, selected areas of myocardium away from the fibrotic areas had been fixed in 2% phosphate-buffered glutaraldehyde, and epon embedded sections were stained with uranyl acetate and lead citrate. The sections were studied using a Philips 300 electron microscope. Examination of these sections showed extensive degeneration and loss of myofibrils, swelling of mitochondria, absence of glycogen granules and dense intramitochondrial deposits. In addition there were multiple areas of fraying of the Z Bands and extension of Z Band substance into the sarcoplasm (Fig. 4).

**Discussion**

The microscopic and ultrastructural changes described in this case are characteristic of the cardiotoxicity associated with adriamycin, and have been described in detail in several reviews. These changes occur infrequently when total cumulative dosages are less than 550 mg/m², although mediastinal irradiation, dactinomycin and cyclophosphamide treatment have been shown to facilitate its development at lower total dosages of adriamycin. Our patient was treated with dactinomycin and cyclophosphamide, but it is worth emphasising that the mediastinum was not irradiated, and the total cumulative dose of adriamycin was relatively low.

Endocardial fibrosis and mural thrombi are reported in cases of adriamycin cardiotoxicity but usually they are relatively minor features. In our patient, the endomyocardial fibrotic change was the most striking anomaly and since the chordae tendinae were not noted.
of the mitral valve were involved, it would have accentuated the effects that any myocardial damage might have had.

Similar morphological changes to those seen in our patient have been described in another patient who was treated with daunorubicin (a close analogue of adriamycin).\textsuperscript{11} Although the conditions in our patient, and the earlier patient\textsuperscript{11} resemble classical African endomyocardial fibrosis, our case lacked the inflammatory infiltrate that is described by some\textsuperscript{12,13}—but not all\textsuperscript{14,15}—reviews of that cardiomyopathy. Whether or not African endomyocardial fibrosis and the changes seen in our patient are indicative of a parallel end-organ response to diverse aetiological agents, toxic myocardial damage—of uncertain origin—has been postulated to be the basis for the development of the classical, African disease.\textsuperscript{15} The supervention of lesions resembling endomyocardial fibrosis in a patient with progressive and diffuse cardiotoxicity may, therefore, provide some insight
Adriamycin cardiotoxicity: report of an unusual case

into the pathological mechanisms involved in classical endomyocardial fibrosis.

We wish to thank Prof WP Cockshott of the Department of Radiology, McMaster University, for his advice, and Mr G Turcon and Mrs S Whittaker for excellent technical assistance.

References


Requests for reprints to: Dr DJ deSa, Department of Pathology, McMaster University Medical Centre, Hamilton, Ontario, Canada L8S 4J9.
Adriamycin cardiotoxicity: report of an unusual case with features resembling endomyocardial fibrosis.

W Fitter, D J deSa and K R Pai

doi: 10.1136/jcp.34.6.602

Updated information and services can be found at: [http://jcp.bmj.com/content/34/6/602](http://jcp.bmj.com/content/34/6/602)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)